Matched primary and metastatic tumor lesions from clinical specimens revealed similar MUC1 immunohistochemical labeling patterns, while a tissue microarray of human PDA biopsies showed an increased immunolabeling with a combination of both MUC1 and mesothelin (MSLN) antibodies, compared with either antibody alone. Here, MUC1 is linked to metastatic neoplasm.